



Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation[☆]

Eva Tejerina MD^a, Fernando Frutos-Vivar MD^a, Marcos I. Restrepo MD^b, Antonio Anzueto MD^b, Fernando Palizas MD^c, Marco González MD^d, Carlos Apezteguía MD^e, Fekri Abroug MD^f, Dimitros Matamis MD^g, Guillermo Bugedo MD^h, Andrés Esteban MD, PhD^{a,*},
for the International Mechanical Ventilation Study Group

^aIntensive Care Unit, Hospital Universitario de Getafe, 28905-Getafe, Madrid, Spain

^bIntensive Care Unit, University of Texas Health Science Center at San Antonio, Texas 78229, USA

^cIntensive Care Unit, Clínica Bazterrica, 1425 Buenos Aires, Argentina

^dIntensive Care Unit, Hospital General de Medellín, Medellín, Colombia

^eIntensive Care Unit, Hospital Nacional Profesor Alejandro Posadas, 1706, Haedo, Argentina

^fIntensive Care Unit, Centre Hospitalo-Universitaire Fattouma Burghuiba, 5000 Monastir, Tunisia

^gIntensive Care Unit, Papageorgiou Hospital, 56429 Thessaloniki, Greece

^hIntensive Care Unit, Universidad Católica de Chile, Santiago, Chile

Received 1 November 2004; revised 15 February 2005; accepted 17 May 2005

Keywords:

Community-acquired pneumonia;
Mechanical ventilation;
Intensive care unit

Abstract

Purpose: To evaluate the variables associated with mortality of patients with community-acquired pneumonia who require mechanical ventilation and to determine the attributable morbidity and intensive care unit (ICU) mortality of community-acquired pneumonia.

Material and Methods: Retrospective cohort study carried out in 361 ICUs from 20 countries including 124 patients who required mechanical ventilation on the first day of admission to the hospital due to acute respiratory failure secondary to severe community-acquired pneumonia. To assess the factors associated with outcome, a forward stepwise logistic regression analysis was performed, and to determine the attributable mortality of community-acquired pneumonia, a matched study design was used.

Results: We found 3 independent variables significantly associated with death in patients with community-acquired pneumonia requiring mechanical ventilation: simplified acute physiological score greater than 45 (odds ratio, 5.5 [95% confidence interval, 1.7-12.3]), shock (odds ratio, 5.7 [95% confidence interval, 1.7-10.1]), and acute renal failure (odds ratio, 3.0 [95% confidence interval,

[☆] This study was supported by grant 98/0233 from the Fondo de Investigación Sanitaria, Spain, and Red GIRA (G03/063) and Red RESPIRA (C03/11) from Instituto de Salud Carlos III, Spain.

* Corresponding author. Tel.: +34 916834982; fax: +34 916832095.

E-mail address: aesteban@ucigetafe.com (A. Esteban).

1.1-4.0]). There was no statistically significant difference in ICU mortality among patients with or without community-acquired pneumonia (32% vs 35%; $P = .59$).

Conclusions: Community-acquired pneumonia needing mechanical ventilation is not a disease associated with higher mortality. The main determinants of patient outcome were initial severity of illness and the development of shock and/or acute renal failure.

© 2005 Elsevier Inc. All rights reserved.

1. Introduction

Community-acquired pneumonia remains a common and serious illness, in spite of the availability of new antimicrobials and successful vaccines. Approximately 10% to 36% of patients with community-acquired pneumonia who need hospitalization require intensive care unit (ICU) treatment [1]. Mortality in these patients has been reported to range from 21% to 58% [2]. Prior investigations have shown that the requirement for mechanical ventilation is associated with increased mortality compared with nonventilated patients [3,4]. There are numerous studies evaluating clinical outcomes of patients with community-acquired pneumonia [2], but these studies included an overall population and the outcome of the subgroup of patients requiring mechanical ventilation has not been evaluated in detail.

The objectives of this study were to evaluate variables associated with mortality of patients with community-acquired pneumonia who require mechanical ventilation from the first day of admission to the hospital and to determine the attributable morbidity and ICU mortality of community-acquired pneumonia.

2. Materials and methods

2.1. Population study

We used the database of a prospective, multicenter, international cohort of 5183 adult patients who received mechanical ventilation for more than 12 hours from March 1, 1998, to March 31, 1998, at 361 ICUs [5]. We included in the study 124 patients (2% of overall population included in the International Study of Mechanical Ventilation) who required mechanical ventilation on the first day of admission to the hospital due to acute respiratory failure secondary to severe community-acquired pneumonia.

The following information was collected on each patient: (a) demographic data (sex, age, previous functional status, weight), date of admission to ICU, and initiating mechanical ventilation; (b) variables related to management (mode of ventilation, respiratory rate, tidal volume, applied positive end-expiratory pressure, airway pressures, need for vasoactive drugs, need for neuromuscular blockers, arterial blood gas analysis). The arterial blood gases correspond to the values obtained once daily at approximately 8:00 AM. The ventilator variables correspond to the

time that the arterial blood gases were obtained. The use of neuromuscular blockers and vasoactive drugs (given for at least 3 hours in a 24-hour period) was recorded daily for a maximum of 28 days; and (c) the development of the following events was assessed daily during the course of mechanical ventilation for a maximum of 28 days: acute respiratory distress syndrome, barotrauma, sepsis, renal failure, hepatic failure, and coagulopathy. A patient was considered to have any of the above conditions if it was present for at least 2 consecutive days. The patients were prospectively followed up for a maximum of 28 days of mechanical ventilation and/or until discharge from the hospital and/or death.

Community-acquired pneumonia was defined as an acute infection of the pulmonary parenchyma that is associated with at least some symptoms of acute lower respiratory infection (fever or hypothermia, rigors, sweats, new cough with or without sputum production or change in color of respiratory secretions in a patient with chronic cough, chest discomfort, or the onset of dyspnea), accompanied by the presence of an acute infiltrate consistent with pneumonia on a chest radiograph, in a patient not hospitalized within 14 days before onset of symptoms [6].

2.2. Statistical analysis

Results were expressed as mean and SD, median with the interquartile range, and proportions as appropriate. We used the Student t test or Mann-Whitney U test to compare continuous variables and the χ^2 test or Fisher test to compare proportions. Significant univariate predictors for mortality were entered into a forward stepwise logistic regression analysis, with criteria entry and exit at $P < .05$ and $P < .10$, respectively. The model's goodness of fit was assessed by the method of Hosmer and Lemeshow.

To determine the attributable morbidity, defined as duration of mechanical ventilation and ICU length of stay, and attributable ICU mortality of community-acquired pneumonia, a matched study design was used, matching each patient with severe community-acquired pneumonia needing mechanical ventilation to a mechanically ventilated patient but without community-acquired pneumonia from our database. The matched variables were variables that we have reported to be associated with mortality in mechanically ventilated patients [5]: (a) variables present at the beginning of mechanical ventilation (age, simplified acute physiological score [SAPS II], limited activity as previous functional status); (b) variables related to patient

management (use of vasoactive drugs, use of neuromuscular blockers, plateau pressure >35 cm H₂O); and (c) complications developing over the course of mechanical ventilation (acute respiratory distress syndrome, sepsis, shock, renal failure, hepatic failure, coagulopathy, and ratio of PaO₂ to FIO₂). The variability range for matching age was ±10 years and for SAPS II was ±10 points.

3. Results

Characteristics of patients who were diagnosed with community-acquired pneumonia needing mechanical ventilation are shown in Table 1. Among these, 40 (32%) patients died during the ICU stay and 46 (37%) patients died during the hospital stay. Among surviving patients (n = 84), the destinations at hospital discharge were as follows: home (74%), nursing home (11%), acute facility (7%), and other destiny (9%).

3.1. Prognosis factors

Nonsurviving patients had a greater severity of illness at ICU admission and more shock, acute renal failure, and coagulopathy over the course of mechanical ventilation (Table 2).

Although a trend was observed toward a better evolution in patients who survived, there were no significant differences in any blood gases parameter except for ratio of PaO₂ to FIO₂. Significant differences were found in this parameter before mechanical ventilation (mean ratio of PaO₂ to FIO₂, 141 ± 71 for nonsurvivors vs 172 ± 89 for survivors; *P* = .05), at first day (mean ratio of PaO₂ to FIO₂, 144 ± 69 vs 179 ± 80; *P* = .03) and last day of mechanical ventilation (mean ratio of PaO₂ to FIO₂, 174 ± 78 vs 213 ± 74; *P* = .01), and in the degree of improving oxygenation (mean difference between last and previous value of ratio of PaO₂

Table 1 Characteristics of patients with community-acquired pneumonia who needed mechanical ventilation (N = 124)

Age (y)	60 (18)
Female sex	42 (34)
SAPS II score (points)	46 (16)
Prior functional state (limited activity)	56 (45)
Use of vasoactive drugs	48 (38)
Use of neuromuscular blockers	17 (14)
Barotrauma	6 (5)
Acute respiratory distress syndrome	8 (6)
Sepsis	17 (14)
Shock	36 (29)
Renal failure	30 (24)
Hepatic failure	10 (8)
Coagulopathy	15 (12)
Metabolic acidosis	6 (5)
Respiratory acidosis	9 (7)

Age and SAPS II score are expressed as mean (SD) and all other values are expressed as number (%).

Table 2 Factors associated with ICU mortality in patients with community-acquired pneumonia (univariate analysis)

	Nonsurvivors (n = 40)	Survivors (n = 84)	<i>P</i>
<i>Variables present at the beginning of mechanical ventilation</i>			
Age (y), mean (SD)	62 (18)	58 (18)	.24
SAPS II (points), mean (SD)	57 (18)	40 (12)	<.001
Female, n (%)	29 (34.5)	13 (32.5)	.82
Prior functional state (limited activity), n (%)	18 (45%)	38 (45%)	.98
Arterial blood gases previous to mechanical ventilation, mean (SD)			
Arterial pH	7.29 (0.11)	7.29 (0.11)	.85
PaCO ₂	51 (21)	52 (19)	.77
Ratio of PaO ₂ to FIO ₂	141 (71)	172 (89)	.05
<i>Variables related with management</i>			
Use of neuromuscular blockers, n (%)	9 (22.5)	9 (11)	.10
Ventilatory management, mean (SD)			
First day of mechanical ventilation			
Tidal volume (mL/kg)	9 (2)	9 (2)	.87
Applied PEEP (mL/kg)	5 (4)	5 (3)	.92
Plateau pressure (cm H ₂ O)	23 (4)	23 (5)	.98
Last day of mechanical ventilation			
Tidal volume (mL/kg)	9 (2)	9 (2)	.79
Applied PEEP (mL/kg)	6 (4)	5 (2)	.25
Plateau pressure (cm H ₂ O)	25 (7)	23 (3)	.10
Arterial blood gases, mean (SD)			
First day of mechanical ventilation			
Arterial pH	7.38 (0.09)	7.38 (0.09)	1.00
PaCO ₂ (mm Hg)	39 (12)	40 (13)	.64
Ratio of PaO ₂ to FIO ₂	144 (69)	179 (80)	.03
Last day of mechanical ventilation			
Arterial pH	7.37 (0.10)	7.40 (0.04)	.05
PaCO ₂ (mm Hg)	40 (9)	39 (6)	.61
Ratio of PaO ₂ to FIO ₂	174 (78)	213 (74)	.01
<i>Complications developing over the course of mechanical ventilation, n (%)</i>			
Barotrauma	3 (7)	6 (7)	1.00
Acute respiratory distress syndrome	4 (10)	4 (5)	.27
Sepsis	8 (20)	9 (11)	.16
Shock	22 (55)	14 (17)	<.001
Acute renal failure	18 (45)	12 (14)	<.001
Hepatic failure	5 (12.5)	5 (6)	.21
Coagulopathy	8 (20)	7 (8)	.08
Metabolic acidosis	3 (7.5)	3 (4)	.34

to FIO₂, 34 ± 81 in nonsurvivors vs 71 ± 96 in survivors; *P* = .05).

Multivariate analysis selected 3 independent variables significantly associated with death: SAPS II greater than 45 (odds ratio, 5.5 [95% confidence interval, 1.7-12.3]), shock (odds ratio, 5.7 [95% confidence interval, 1.7-10.1]), and acute renal failure (odds ratio, 3.0 [95% confidence interval, 1.1-4.0]).

3.2. Impact on outcome

Overall, 124 patients with severe community-acquired pneumonia requiring mechanical ventilation were successfully matched to a control patient without community-acquired pneumonia. Characteristics and outcomes of cases and controls are shown in Table 3.

There was no statistically significant difference in ICU mortality among patients with or without community-acquired pneumonia needing mechanical ventilation (32% vs 35%; $P = .59$).

There were no statistically significant differences in duration of mechanical ventilation (median, 5 days [interquartile range, 3-8 days] vs 4 days [interquartile range, 2-6 days]; $P = .23$) nor in length of stay (median, 8 days [interquartile range, 4-15 days] vs 6 days [interquartile range, 4-13 days]; $P = .55$) compared with patients without community-acquired pneumonia.

Table 3 Comparison of patients with community-acquired pneumonia requiring mechanical ventilation and their matched controls

	Cases (N = 124)	Controls (N = 124)	<i>P</i>
<i>Variables present at the beginning of mechanical ventilation</i>			
Age (y), mean (SD)	60 (18)	59 (17)	.83
SAPS II (points), mean (SD)	46 (16)	45 (16)	.82
Prior functional state (limited activity), n (%)	56 (45)	57 (46)	.97
<i>Variables related with management, n (%)</i>			
Use of vasoactives	48 (39)	45 (36)	.69
Use of neuromuscular blockers	17 (14)	13 (10)	.44
Plateau pressure >35 cm H ₂ O	6 (5)	4 (3)	.52
<i>Complications developing over the course of mechanical ventilation, n (%)</i>			
Barotrauma	6 (5)	5 (4)	.76
Acute respiratory distress syndrome	8 (6)	8 (6)	1.00
Sepsis	17 (14)	17 (14)	1.00
Shock	36 (29)	37 (30)	.89
Acute renal failure	30 (24)	32 (26)	.77
Hepatic failure	10 (8)	9 (7)	.81
Coagulopathy	15 (12)	15 (12)	1.00
Metabolic acidosis	6 (5)	8 (6)	.58
Ratio of PaO ₂ to FIO ₂ ≤200	106 (85)	102 (83)	.68
<i>Outcomes</i>			
Days of mechanical ventilation, median (IQR)	5 (3-8)	4 (2-6)	.23
Length of stay in the ICU, median (IQR)	8 (4-15)	6 (4-13)	.55
ICU mortality (%)	32	35	.59

IQR indicates interquartile range.

4. Discussion

The main findings of our study were that community-acquired pneumonia requiring mechanical ventilation is not associated with increase ICU mortality and it did not prolong either the duration of mechanical ventilation or the ICU length of stay. Factors significantly associated with outcome were severity of illness at ICU admission and development of cardiovascular and renal dysfunction over the course of mechanical ventilation.

In the outpatient setting, the mortality rate of pneumonia remains in the range of 1% to 5%, but among patients with community-acquired pneumonia who require hospitalization, the mortality rate increases to 12%, and in specific populations such as those with bacteremia or patients requiring admission to ICU, mortality ranges from 21% to 58% [2,7-10]. In our series, the mortality in the ICU of patients with community-acquired pneumonia requiring mechanical ventilation was 32%, in the lower range of those previously reported [7,11,12].

Several studies have analyzed the factors associated with outcome of patients with community-acquired pneumonia [13]. These factors, analyzed in a large systematic review of the literature [2] and further studies [4,7-15], can be divided into baseline variables (male sex, age, presence of coexisting disease, living in a nursing home, underlying immunosuppression or neoplasm); severity at admission at hospital (SAPS II >10-13, decreased level of consciousness, tachypnea); factors related with the pneumonia (radiographic spread of pneumonia or bilateral pulmonary involvement, aspiration pneumonia, infection caused by aerobic gram-negative pathogens, the extent of lung injury, bacteremia, requirement of mechanical ventilation, ineffective initial antibiotic therapy); and factors related with extrapulmonary complications (hypothermia, leukopenia, sepsis, septic shock, renal failure, the number of non-pulmonary organs that failed). In our cohort of mechanically ventilated patients, the variables associated with worse outcome were severity of illness on admission at ICU, shock, and acute renal failure. Although variables related to oxygenation and pulmonary parameters were not associated with outcome, we found a trend toward a better evolution in patients who survived. In a validation study of American Thoracic Society guideline severity criteria for community-acquired pneumonia by Ewig et al [7], criteria reflecting impaired oxygenation (respiratory rate >30/min and PaO₂/FIO₂ <250 at admission) were insensitive, nonspecific, and only weakly associated with mortality from severe pneumonia. To our knowledge, there are no previous studies concerning the potential prognostic value of oxygenation and pulmonary parameters over the whole course of mechanical ventilation in patients with severe community-acquired pneumonia. Most studies have evaluated hypoxemia at presentation [12,15] or over the first 24 hours of mechanical ventilation [11]. The strengths of our study were the use of a matching procedure to examine

the morbidity and mortality attributable to community-acquired pneumonia needing mechanical ventilation. In the present study, we found a control similar to each patient with community-acquired pneumonia requiring mechanical ventilation using 12 predefined variables associated with mortality [5]. We have used data from an international multicenter database adding to the validity and generalizability of the obtained results. Our sample size was large and we only included mechanically ventilated patients, whereas most of the prior studies of severe community-acquired pneumonia had mixed populations of ventilated and nonventilated patients.

We must address several limitations of our study. First, we have only used clinical criteria to diagnose pneumonia, and therefore, it has not been ascertained the importance of other potential determinants of patient outcome such as the specific microorganism responsible and the adequacy of initial antimicrobial therapy. In this sense, although some authors have observed that identifying the etiologic agent and adjusting treatment both impact patient outcome [12,16], most studies have demonstrated that causative agent was not related with outcome [2,17]. Prior antibiotic administration and adequacy of initial antimicrobial therapy were not considered in this study. Second, in our series, we did not study, as a prognostic factor, the radiographic spread of the pneumonia at ICU admission. However, in the validation study by Ewig et al [7], the two baseline radiographic criteria (multilobar or bilateral involvement in chest radiograph) had a high specificity but remained insensitive and had low positive predictive values. These observations could be due to the fact that the correlation of severe pneumonia with the extension of infiltrates visible on chest radiograph was only moderate. Third, we only took into account limited activity as prior functional status and did not account for chronic obstructive pulmonary disease, alcoholism, diabetes mellitus, and chronic heart failure, which were shown to be related with poor outcome in previous studies [4,14]. However, some other authors did not find comorbidities to influence outcome [9].

In summary, despite the above-mentioned limitations, we have found that community-acquired pneumonia needing mechanical ventilation is not a factor associated with mortality as compared with patients on mechanical ventilation for other reasons, controlling for potential confounding variables. And, it does not prolong either duration of mechanical ventilation or ICU length of stay. We also observed that initial severity of illness and the development of shock and/or acute renal failure were main determinants of patient outcome.

Appendix A

The investigators for the International Mechanical Ventilation Study Group were the following:

ARGENTINA: *Coordinators: C Apezteguia, F Palizas.* R Alasino (Hospital Municipal de Urgencias, Córdoba); R Bastianelli (Hospital Militar, Villa Revol); J Berón (Hospital Pablo Soria, San Salvador); C Bevilacqua (Clínica Modelo de Morón, Morón); M Cafaro (Hospital Regional Río Gallegos, Río Gallegos); E Capparelli (Hospital Eva Perón, San Martín); G Cardonatti (Hospital San Isidro, San Isidro); R Correa (Hospital Central, Mendoza); A Díez (Hospital Provincial del Centenario, Rosario); E Estensoro (Hospital Escuela José de San Martín, La Plata); J Fara (Policlínico Ferroviario, Rosario); R Fernández (Hospital Italiano, Guaymallén); G Fernández Cid (Hospital E Tomú, Buenos Aires); H Ferraro (Corporación Médica de San Martín, San Martín); A Galaverna (Hospital Zonal Bariloche, Bariloche); C Galleti (Sanatorio Allende, Córdoba); G García (Hospital Clemente Álvarez, Rosario); G Gelardi (Hospital Privado del Sur, Bahía Blanca); S Giannasi (Hospital Italiano, Buenos Aires); R Guidi (Hospital Italiano Garibaldi, Rosario); L Huespe Gardel (Hospital Escuela José F de San Martín, Corrientes); C Irrazábal (Hospital de Clínicas José de San Martín, Buenos Aires); O López (Sanatorio Santa Isabel, Buenos Aires); G Menga (Hospital María Ferrer, Buenos Aires); O Otero (Centro Oncológico de Excelencia, Gonnet); F Pálizas (Clínica Bazterrica, Buenos Aires); P Pardo (Sanatorio de la Trinidad, Buenos Aires); C Plaza (Sanatorio Julio Méndez, Buenos Aires); G Raimondi (FLENI, Buenos Aires); A Raimondi (Sanatorio Mater Dei, Buenos Aires); E Romero (Hospital Privado Centro Médico, Córdoba); L de Rosa (Sanatorio Quintar, San Salvador); C Sáez (Sanatorio Británico, Rosario); A Sarsino (Hospital Juan A Fernández, Buenos Aires); P Schoon (Hospital Prof Luis Güemes, Haedo); C Sola (Hospital José Penna, Bahía Blanca); C Stöltzing (Hospital Guillermo Rawson, San Juan); J Taccone (Instituto Alfredo Lanari, Buenos Aires); C Tolosa (Hospital Córdoba, Córdoba); M Torreno (Sanatorio Modelo Quilmes, Quilmes); E Turchetto (Hospital Privado de la Comunidad, Mar de Plata); R Valenti (CEMIC, Buenos Aires); R Vargas (Policlínico Neuquen, Neuquen); L Vasta (Sanatorio San Patricio, Buenos Aires); L Vázquez (Hospital Español, Godoy Cruz); Vetere (Hospital Israelita Ezra, Buenos Aires); F Villarejo (Hospital Prof Alejandro Posadas, Haedo); N Wainsztein (Hospital Privado Fundación Favaloro, Buenos Aires); O Yunk (Hospital Español, Buenos Aires); G Zabert (Clínica Pasteur, Neuquen). BOLIVIA: *Coordinator: F Sandi Lora.* L Moya (Hospital Juan XXIII, La Paz); E Salazar (Hospital Japonés, Santa Cruz); JC Zapata (Hospital Obrero, La Paz). BRAZIL: *Coordinator: CM David.* SM Ajeje Lobo (Hosp de Base de São José do Rio Preto, São José do Rio Preto); AB de Almeida (Hospital das Clínicas da Univers Federal, Uberlândia); MA Braga (Hospital Biocor, Belo Horizonte); I Buselato Chen (Hospital Nossa Senhora das Graças, Curitiba); M Chaves Craveiro de Melo (Hospital São Lucas, Belo Horizonte); RN Darwich (Hospital Pronto-corr, Belo Horizonte); CM David (Hospital Clementino Fraga

Filho, Rio de Janeiro); R Goldstein Alheira Rocha (Hospital Samaritano, São Paulo); R de Macedo Bosco (Hospital Madre Teresa, Belo Horizonte); JM Nogueira (Hospital Universitario São José, Belo Horizonte); E Oliveira (Hospital Vera Cruz, Belo Horizonte); SF Pinto (Casa de Saúde São José, Campo Grande); SF Pinto (Santa Casa de Campo Grande, Campo Grande); SF Pinto (Univ Fed Mato Grosso do Sul, Campo Grande); JL da Rocha Paranhos (Santa Casa de Misericórdia, São João del Rei); LR de Siqueira Musolino (Irmandade da Santa Casa de Misericórdia, São Paulo). CANADA: *Coordinator: TE Stewart*. R Fowler (Wellesley-Central Hospital, Toronto). J Granton (Toronto Hospital General Division, Toronto); J Granton (Toronto Hospital Western Division, Toronto); R Hodder (Ottawa Civic Hospital, Ottawa); B Kashin (Peel Memorial Hospital, Brampton-Ontario); S Lapinsky (Mount Sinai Hospital, Toronto); D Mazer (St Michael's Hospital, Toronto); R McLean (Sunnybrook Health Sciences Centre, Toronto); T Rogovein (St Joseph's Health Centre, Toronto). CHILE: *Coordinator: L Soto*. G Buguedo (Hospital Pontificia Universidad Católica, Santiago); P Hernández (Instituto Nacional del Tórax, Santiago); C Ortega (Hospital Regional Concepción, Concepción); L Soto (Hospital de Coquimbo, Coquimbo); L Schölz (Hospital de Osorno, Osorno). COLOMBIA: *Coordinator: M González*. H Atehortua (Clínica Sta María, Centro Cardiovascular, Medellín); C Cadavid (Hospital Pablo Tobón Uribe, Medellín); D Camargo (Hospital Universitario, Barranquilla); C Dueñas (Hospital Universitario, Cartagena); A Guerra (Hospital General, Medellín); M Granados (Fundación Valle de Lilly, Cali); R Panesso (Clínica Las Américas, Medellín); MA Perafán (Clínica Shaio, Bogotá). ECUADOR: *Coordinator: J Raad*. B Guevara (Hospital Carlos Andrade, Quito); J Molina (Hospital Militar, Quito); J Raad (Hospital Militar, Quito). FRANCE: *Coordinator: L Brochard*. P Andrivet (Centre Médico-Chirurgical de Bligny, Bris-sous-Forges); D Annane (Hôpital Raymond Poincaré, Garches); C Arich (CHU de Nîmes, Nîmes); F Baud (Hôpital Lariboisière, Paris); F Bellenfant (Hôpital Cochin, Paris); R Boiteau (Hôpital Louise Michel, Evry); F Brivet (Hôpital A Béclère, Clamart); M Canonne (CHG Les Feugrais, Elbeuf); JP Cardinaud (Hôpital Pellegrin-Tripode, Bourdeaux); E Clémenti (Centre Hosp Dept, La Roche/Yon); P Charbonneau (CHU Côte de Nacre, Caen); J Chastre (Hôpital Bichat, Paris); R Chauveau (CH André Grégoire, Montreuil-Ss-Bois); C Chopin (CHRU-Hôpital B, Lille); JM Descamps (Centre Hospitalier de Niort, Niort); D Dreyfuss (Hôpital Louis Mourier, Colombes); JP Faller (C Hosp de Belfort, Belfort); F Fraisse (Hôpital Delafontaine, Saint-Denis); C Girault (Hôpital Charles Nicolle, Rouen); C Guérin (Hôpital Croix Rousse, Lyon); E Guerot (Hôpital Boucicaut, Paris); F Hilpert (Hôpital Ballanger, Aulnay-sous-Bois); L Holzapfel (Centre Hospitalier, Bourg-en-Bresse); F Jardin (Hôpital Ambroise Paré, Boulogne Vignancourt); O Jonquet (Hôpital Gui de Chauillac, Montpellier); E L'Her (CHU de la Cavale

Blanche, Brest); Y Lefort (Hôpital Henri Mondor, Creteil); O Leroy (Centre Hospitalier, Tourcoing); Y Le Tulzo (CHU Pontchaillon, Rennes); Ch Mayaud (Hôpital Tenon, Paris); H Mentec (Hôpital Victor Dupouy, Argenteuil); A Mercat (Hôpital Bicêtre, Kremlin-Bicêtre); B Misset (Hôpital Saint-Joseph, Paris); P Moine (Hôpital Bicêtre, Bicêtre); G Nitemberg (IGR, Villejuif); L Papazian (Hôpital Sainte Marguerite, Marseille); A Rabbat (Hôpital Hôtel-Dieu, Paris); T Similowski (Hôpital Pitié Salpêtrière, Paris); L Soufir (Hôpital Saint-Louis, Paris); D Tardy (Hôpital Saint-Camille, Bry-sur-Marne); F Thaler (CM Chirurgical Foch, Suresnes); B Vallet (Centre Hospitalier Univ, Lille); D Villers (CHU Nantes, Nantes); M Wysocki (Institut Mutualiste Montsouris, Paris); JF Zazzo (Hôpital A Béclère, Clamart). GREECE: *Coordinator: D Matamis*. D Georgopoulos (Heraklion University Hospital, Heraklion); M Gianakou (Ahepa University Hospital, Thessaloniki); D Lagonidis (Papanikolaou Hospital, Thessaloniki); G Nakos (Ioanina University Hospital, Ioanina); K Stavrakaki (Evangelismos Hospital, Athens); G Thomopoulos (Laikon Hospital, Athens). IRELAND: *Coordinator: G Fitzpatrick*. M Donnelly (Adelaide and Meath Hospital, Dublin); J Moriarty (St James Hospital, Dublin); B O'Sullivan (Waterford Regional Hospital, Waterford); G Shorten (Cork University Hospital, Cork). ITALY: *Coordinator: P Pelosi*. Cositi (Pol Umberto I, Roma); G Iapichino (Hospital S Paolo, Milano); P Pelosi (Policlinico, Milano); A Pesenti (Dsp S Gerardo, Monza). MEXICO: *Coordinator: J Elizalde*. F Aguilera Almazán (Hospital General Regional No 1, Chihuahua); M Benitez Cortazar (Hospital Universitario de Puebla, Puebla); R Carrillo Speare (Hospital PEMEX Sur, México DF); R Castaño (Hospital de Cardiología del CMN, México DF); R Corral (Hospital Excel, Tijuana, Baja California); DM D'Ector Lira (Hospital Metropolitano, México DF); G Díaz Polanco (Hospital de Traumatología Magdalena de las Salinas, México DF); JJ Elizalde (Hospital ABC, México DF); R Envila Fisher (Hospital Morelos, Chihuahua); R Envila Fisher (Hospital Clínica del Parque, Chihuahua); G Franco G (Hospital General de México, México DF); P García Balbuena (Hospital General "Fernando Quiroz," México DF); O Gayoso Cruz (Hospital Regional "Adolfo López Mateos," México DF); L Green (Instituto Nacional de Cancerología, México DF); JO Herrera Hoyos (Centro Médico Las Américas, Mérida); J Hinojosa (Hospital Angel Leño, Guadalajara); J Huerta (Clínica Londres, México DF); VA Juárez (Hospital Santelena, México DF); M Loera (Hospital General Durango, Durango); C López Alzate (Clínica del Mar, Mazatlán); E López Mora (Instituto Nacional de Cardiología, México DF); S Martínez Cano (Hospital Hidalgo Aguascalientes, Aguascalientes); R Mendez Reyes (Hospital Regional 1° de Octubre, México DF); M Mendoza (Hospital General de la Villa, México DF); O Narváez Porras (Instituto Nacional de Enfermedades Respiratorias, México DF); E Ortiz (Hospital General Irapuata, Guana-

juato); A Padua (Hospital General Torreón, Coahuila); M Poblano (Hospital Juárez, México DF); V Pureco Reyes (Hospital Regional “20 de Noviembre,” México DF); W Querevalum (Hospital Central Cruz Mexicana, México DF); A Quesada (Hospital Ntra Sra de la Salud, San Luis Potosí); A Ramírez Rivera (Hospital de Enfermedades Cardiovasculares y del Tórax, IMSS, Monterrey); A Tamariz (Hospital Clínica del Centro, Chihuahua); A Tamariz (Hospital Central Universitario, Chihuahua); A Vargas (Hospital General de Pachuca, Pachuca); C Vázquez (Hospital General Celaya, Guanajuato). PERU: *Coordinator: AM Montañez*. M Contardo (Edgardo Rebagliati Martins–UCI 7°B, Lima); E Durand (Guillermo Almenara Irigoyen–IPPS, Lima); M Manrique (Hospital “Jose Casimiro Ulloa,” Lima); JC Meza (Centro Médico Naval, Lima); J Muñoz (Edgardo Rebagliati Martins–UCI 2°C, Lima); J Pacheco (Hospital del Apoyo “María Auxiliadora,” Lima); C Salcedo (Hosp Nacional “Daniel Alcides Carrión,” Lima); J Silva (Hospital Central FAP, Lima); C Torres (Hospital Nacional “Arzobispo Loayza,” Lima). PORTUGAL: *Coordinator: J Pimentel*. P Amaro (Centro Hospitalario de Gaia, Gaia); F Faria Instituto Português de Oncología, Porto); P Freitas (Hospital Fernando da Fonseca, Amadora–Sintra); P Martins (Hospital Universidade, Coimbra); E Sabino (Hospital García de Orta, Almada); J Salcher (Hospital de San José, UUM, Lisboa); E Silva (Hospital Senhora do Desterro, Lisboa). SPAIN: *Coordinators: A Esteban, F Frutos-Vivar*. JM Allegre (Hospital Nuestra Señora del Rosell, Cartagena); S Alonso (Hospital Joan XXIII, Tarragona); A Alvarez Ruiz (Hospital General Río Carrión, Palencia); B Alvarez Sánchez (Hospital General, Alicante); MT Antuna (Hospital de Cabueñes, Gijón); JM Añón (Hospital Virgen de la Luz, Cuenca); P Arribas (Hospital 12 de Octubre, Madrid); A Ayensa (Hospital Virgen de la Salud, Toledo); A Azcárate (Hospital Nuestra Señora de Aranzazu, Donostia); J Blanco (Hospital del Río Hortega, Valladolid); GM Besso (Hospital Carlos Haya, Málaga); L Cabré (Hospital de Barcelona, Barcelona); F Carrizosa (Hospital General, Jerez de la Frontera); J Castañeda (Hospital Clínico, Valladolid); R de Celis (Hospital de Galdakao, Galdakao); JA Conesa (Hospital Clínico Universitario San Carlos, Madrid); J Diarte (Complejo Hospitalario, Ciudad Real); A Díaz Lamas (Complejo Hospitalario Cristal Piñor, Orense); R Fernández (Consorcio Hospitalari del Parc Taulí, Sabadell); M Ferrer (Hospital Clinic i Provincial, Barcelona); D Fontaneda (Hospital Virgen Blanca, León); P Galdós (Hospital General, Móstoles); A García Jiménez (Hospital Arquitecto Marcide, El Ferrol); J García Pardo (Hospital Juan Canalejo, La Coruña); J Gener (Hospital Germans Trias i Pujol, Badalona); JA Gómez Rubí (Hospital Virgen de la Arrixaca, Murcia); G González Díaz (Hospital Morales Meseguer, Murcia); S González Prado (Hospital Josep Trueta, Girona); C Homs (Hospital General San Jorge, Huesca); J Ibañez (Hospital Son Dureta, Palma de Mallorca); F Jara (Hospital Mutua,

Terrassa); M León (Hospital Amau de Vilanova, Lleida); A Lloria (Complejo Hospitalario Rebullón, Pontevedra); J López Díaz (Hospital La Paz, Madrid); MaR Lorenzo (Complejo Hospitalario Materno-Infantil, Las Palmas de Gran Canaria); S Macías (Hospital General, Segovia); JA Maldonado (Hospital de la Serranía, Ronda); J Maynar (Hospital Santiago Apostol, Vitoria); A Moreno (Complejo Hospitalario de San Millán-San Pedro, Logroño); A Mota (Hospital General Universitario, Elche); T Mut (Hospital General, Castellón); M Nolla (Hospital General de Cataluña, Sant Cugat del Vallés); F Ortega (Hospital Universitario de Valme, Sevilla); R de Pablo (Hospital Príncipe de Asturias, Alcalá de Henares); E Palazón (Hospital General Universitario, Murcia); V Parra (Hospital de Sagunto, Sagunto); A Peral (Hospital Gregorio Marañón, Madrid); JC Portela (Complejo Hospitalario Xeral-Calde, Lugo); A Ramírez (Hospital Nuestra Señora de Sonsoles, Avila); JA Ramos (Hospital de Poniente, El Ejido); P Revuelta (Hospital Universitario de Canarias, La Laguna); M Rey (Complejo Hospitalario, Santiago de Compostela); JJ Rodrigo (Hospital Nuestra Señora del Pino, Las Palmas de Gran Canaria); JC Rodríguez Borregan (Hospital Marqués de Valdecilla, Santander); JA Rodríguez Sarria (Hospital General, Elda); A Rubio (Hospital Ramón y Cajal, Madrid); S Ruiz Navarro (Hospital General Ciudad de Jaen, Jaen); V Sagredo (Hospital Virgen de la Vega, Salamanca); P Saura (Centre Hospitalari, Manresa); MJ Serralta (Hospital Universitario de San Juan, Alicante); JF Solsona (Hospital del Mar, Barcelona); F Suárez Sipmann (Fundación Jiménez Díaz, Madrid); F Taboada (Hospital General de Asturias, Oviedo); S Temprano (Hospital Severo Ochoa, Leganés); JP Tirapu (Hospital de Navarra, Pamplona); M^aV de la Torre (Hospital Universitario Virgen de la Victoria, Málaga); P Ugarte (Hospital Marqués de Valdecilla, Santander); M Valledor (Hospital de San Agustín, Avilés); I Vallverdú (Hospital de la Santa Creu i Sant Pau, Barcelona); C Vaquerizo (Hospital 12 de Octubre, Madrid); A Viñuales (Hospital Lluís Alcanyis, Xàtiva). TUNISIA: *Coordinator: F Abroug*. A Bchiz (Hospital F Bached, Sousse); J Ben Khelil (Hospital A Mami, Ariana); S Bern Lakhel (Hospital Rabta, Tunis); B Bouhaja (Hospital Mongi Slim, La Marsa); H Chelly (Hospital Fattouma Bourguiba, Sfax); S El Atrous (Hospital Fattouma Bourguiba, Monastir); S Ghedira (Hospital Charles Nicolle, Tunis); H Thabet (CAMUR Tunis). UNITED KINGDOM: *Coordinator: P Nightingale*. O Akinpelu (Chorley & District Hospital, Chorley); D Bardgett (Macclesfield District General Hospital, Macclesfield); A Batchelor (Royal Victoria Infirmary, Newcastle upon Tyne); R Beale (Guy’s Hospital, London); K Burchett (Queen Elizabeth Hospital, King’s Lynn); N Coleman (North Staffordshire Royal Infirmary, Stoke on Trent); A Conn (Wansbeck General Hospital, Ashington); D Edbrooke (Royal Hallamshire Hospital, Sheffield); N Fergusson (Countess of Chester Hospital, Chester); I Grant (Rotherham District

Hospital, Rotherham); K Gunning (Addenbrooke's Hospital, Cambridge); J Harper (Royal Liverpool University Hospital, Liverpool); D Higgins (Southend Hospital, Westcliffe-on-Sea); D Jayson (Southport & Formby General Hospital, Southport); R Loveland (Wexham Park Hospital, Slough); L Lynch (Birmingham Heartlands Hospital, Birmingham); I Macartney (North Manchester General Hospital, Manchester); E Major (Morrison Hospital, Swansea); S Mousdale (Blackburn Royal Infirmary, Blackburn); N Soni (Chelsea and Westminster Hospital, London); D Watson (Walsgrave Hospital, Walsgrave). URUGUAY: *Coordinator: C Rodrigo*. H Bagnulo (Maciel, Montevideo); C Rodrigo (Asociación Española Primera, Montevideo); M Rodríguez (Hospital de Paysandú, Montevideo). UNITED STATES: *Coordinator: A Anzueto*. SM Aguayo (Atlanta VA Medical Center, Decatur); R Alagar (Allegheny General Hospital, Pittsburgh); RK Albert (Denver Health Medical Center, Denver); TK Aldrich (Montefiore Hospital & Medical Center, Bronx); K Amoosa (Medical College of Wisconsin, Milwaukee); N Anandarao (New York Methodist Hospital, Brooklyn); DC Angus (University of Pittsburgh, Pittsburgh); AC Arroliga (Cleveland Clinic Foundation, Cleveland); MF Azrieli (Jacobu Medical Center, Bronx); RA Balk (Medical Center-203 Jelke, Chicago); PW Bates (Maine Medical Center, Portland); JF Beamis, Jr (Lahey Hitchcock Medical Center, Burlington); PE Bellamis (Chs Dept of Medicine, Los Angeles); DJ Bower (Atlanta VA Medical Center, Decatur); JP Bradley (William Beaumont Medical Center, El Paso); RP Byrd, Jr (University of East Tennessee, Jonesboro); VJ Cardenas, Jr (University of Texas Medical Branch, Galveston); LJ Caruso (University of Florida, Gainesville); BR Celli (St Elizabeths Medical Center, Boston); G Clermon (University of Pittsburgh, Pittsburgh); SJ Coole (Carl T. Hayden VA Medical Center, Phoenix); TA Dillard (Commander MCHJ-MPU, Tacoma); LE Efferen (SUNY Health Science Center, Brooklyn); EW Ely, Jr (Vanderbilt Lung Transplant Program Newline, Nashville); P Factor (Michael Reese Hospital & Medical Center, Chicago); TM Fitzpatrick (Walter Reed Army Medical Ctr, Wash); R Fowler (Wellesley-Central, Toronto); GN Giacompe, Jr (MCHJ-MPU, Tacoma); KK Guntupalli (Texas Med Ctr-Ben Taub Gen Hospital, Houston); JB Hall (University of Chicago, Chicago); ME Hanley (Denver Medical Center, Denver); MT Haupt (Oregon Health Science University, Portland); GB Hayes (St Elizabeths Medical Center, Boston); DE Heiselman (Akron General Medical Center, Akron); FC Hiller (University of Arkansas Med Science, Little Rock); JD Hinze (The University of Texas Health Science Center at San Antonio, San Antonio); RD Hite (Bowman Gray School of Medicine, Winston-Salem); RC Hyzy (Henry Ford Hospital, Detroit); A Jubran (Edward Hines VA Hospital, Hines); CA Kaplan (University of Missouri Columbia, Columbia); MS Karetzky (Newark Beth Israel Med Ctr, Newark); SA Kurenhy (Truman Medical Center, Kansas); KV Leeper, Jr (Emory

University School of Medicine, Atlanta); H Levy (University of New Mexico, Albuquerque); T Lo (Loma Linda University, Loma Linda); MJ Mador (Buffalo VA Medical Center, Buffalo); GP Marelich (University of California Davis Med Ctr, Sacramento); MA Matthay (University of California, San Francisco); NR McIntyre (Duke University Medical Center, Durham); SA Metter (Maine Medical Center, Portland); MS Niederman (Winthrop University Hospital, Mineola); JR Norman (University of Mississippi Medical Center, Jackson); DR Oullette (Brooke Army Medical Center, Fort Sam Houston); P Parsons (Denver Medical Center, Denver); RG Patel (VA Medical Center, Jackson); RC Perkins, II (University of Texas Health Center at Tyler, Tyler); ME Petrini (University of Mississippi Medical Center, Jackson); MR Pinsky (University of Pittsburgh, Pittsburgh); A Pohlman (Edward Hines VA Hospital, Hines); KW Presberg (Medical College of Wisconsin, Milwaukee); MP Rocha (Carl T. Hayden VA Medical Center, Phoenix); W Rodríguez Cintron (San Juan VA Medical Center, San Juan); MJ Rosen (Beth Israel Medical Center, New York); TM Roy (James Quillen College of Medicine, Mountain Home); G Rudelfeld (Harborview Medical Center, Seattle); MJ Rumbak (University Florida, Tampa); SJ Ruoss (Stanford University Medical Center, Stanford); GA Schmidt (University of Chicago, Chicago); RF Schneider (Beth Israel Medical Center, New York); CN Sessler (Medical College of Virginia, Richmond); CS Shim (Jacobi Medical Center, Bronx); L Smith (Rush-Presbyterian-St Lukes Medical Center, Chicago); C Strange (MUSC 96 Jonathan Lucas St, Charleston); JI Sznajder (Michel Reese Hospital & Medical Center, Chicago); S Tessler (Maimonides Medical Center, Brooklyn); V Whyte (Loma Linda University, Loma Linda); L Wilkemyer (Loma Linda University Medical Center MC 1521, Loma Linda); RG Wundering (501 Crews Wing, Memphis); MH Zaman (The Brookdale Hosp Med Ctr, Brooklyn); LH Zimmerman (San Francisco VA Medical Center, San Francisco). VENEZUELA: *Coordinator: G D'Empaire*. J España (Hospital Universitario, Caracas); F Pérez (Hospital de Clínicas, Caracas); R Zerpa (Hospital Militar, Caracas).

References

- [1] Torres A, El Ebiary M, Zavala E, Hernández C. Severe community-acquired pneumonia. *Semin Respir Crit Care Med* 1996;17:265-71.
- [2] Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. *JAMA* 1996;275:134-41.
- [3] Leroy O, Georges H, Beuscart C, et al. Severe community-acquired pneumonia in ICUs: prospective validation of a prognostic score. *Intensive Care Med* 1996;22:1307-14.
- [4] Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. *J Infect Dis* 2000;182:840-7.
- [5] Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation. A 28-day international study. *JAMA* 2002;287:345-55.

- [6] Barlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2000;31:347-82.
- [7] Ewig S, Ruiz M, Mensa J, Marcos MA, et al. Severe community-acquired pneumonia. Assessment of severity criteria. *Am J Respir Crit Care Med* 1998;158:1102-8.
- [8] Alvarez-Sanchez B, Alvarez-Lerma F, Jorda R, Serra J, Lopez-Cambra MJ, Sandar MD. Prognostic factors and etiology in patients with severe community-acquired pneumonia admitted at the ICU. Spanish multicenter study. Study Group on Severe Community-Acquired Pneumonia in Spain. *Med Clin* 1998;111:650-4.
- [9] Georges H, Leroy O, Vandenbussche C, et al. Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. *Intensive Care Med* 1999;25:198-206.
- [10] Leroy O, Devos P, Guery B, Georges H, Vandenbussche C, Coffinier C, et al. Simplified prediction rule for prognosis of patients with severe community-acquired pneumonia in ICUs. *Chest* 1999;116:157-65.
- [11] Pascual FE, Matthay MA, Bacchetti P, Wachter RM. Assessment of prognosis inpatients with community-acquired pneumonia who required mechanical ventilation. *Chest* 2000;117:503-12.
- [12] Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia etiology, epidemiology, and outcome at a teaching hospital in Argentina. *Chest* 2000;118:1344-54.
- [13] Gilavert MC, Bodi M. Factores pronósticos en la neumonia comunitaria grave. *Med Intensiva* 2004;28:419-24.
- [14] Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcome Research Team cohort study. *Arch Intern Med* 2002;162:1059-64.
- [15] Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community acquired pneumonia. *N Engl J Med* 1997;336:243-50.
- [16] Almirall J, Mesalles E, Klamburg J, et al. Prognostic factors of pneumonia requiring admission to the intensive care unit. *Chest* 1995;107:511-6.
- [17] Levy M, Dromer F, Brion N, Leturdu F, Carbon C. Community-acquired pneumonia. Importance of initial noninvasive bacteriologic and radiographic investigations. *Chest* 1988;92:43-8.